BAX vs ICU vs DVA vs HOLX

For growth investors, DaVita Inc.

(DVA) is the stronger pick with 6. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). DaVita Inc. (DVA) offers the better valuation at 20. 6x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Baxter International Inc. (BAX) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DaVita Inc.

(DVA) is the cheapest at 20. 6x versus Hologic, Inc. at 30. 5x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, DaVita Inc.

(DVA) delivered a total return of +54. 8%, compared to -98. 1% for SeaStar Medical Holding Corporation (ICU). Over 10 years, the gap is even starker: DVA returned +158. 1% versus ICU's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DaVita Inc.

(DVA) is the lower-risk stock at 0. 05β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 2793% more volatile than DVA relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 13% for DaVita Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DaVita Inc.

(DVA) is pulling ahead at 6. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: SeaStar Medical Holding Corporation grew EPS 78. 1% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, DVA leads at 5. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -183. 9% for SeaStar Medical Holding Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -132. 2% for ICU. At the gross margin level — before operating expenses — ICU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Baxter International Inc.

(BAX) trades at 9. 2x forward P/E versus 17. 2x for Hologic, Inc. — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BAX: 12. 8% to $19. 75.

In this comparison, BAX (3.

9% yield) pays a dividend. ICU, DVA, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DaVita Inc.

(DVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), +158. 1% 10Y return). Both have compounded well over 10 years (DVA: +158. 1%, ICU: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BAX is a small-cap income-oriented stock; ICU is a small-cap quality compounder stock; DVA is a mid-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. BAX pays a dividend while ICU, DVA, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.